In this episode, Renslow Sherer, MD, discusses key data on COVID-19 oral antiviral agents—molnupiravir and nirmatrelvir (PF-07321332) plus ritonavir—for nonhospitalized adults with mild to moderate COVID-19, including:EPIC-HR study of nirmatrelvir (PF-07321332) plus ritonavirSafety dataEfficacy dataMOVe-OUT study of molnupiravirSafety dataEfficacy dataRoles in treatment of COVID-19Timing of treatmentPresenter:Renslow Sherer, MDDirector, International HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisReview the downloadable slideset at:https://bit.ly/31wi1QiLink to full program:https://bit.ly/3EH2485 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related